AstraZeneca PLC (AZN) annual results, year to 31 December 2017: revenue USD 22,465 million, from the 20-F
AstraZeneca PLC files a 20-F with the SEC once a year, in US dollars. In the year to 31 December 2017 it reported revenue of USD 22,465 million, down 2.3% on the year before. Its profit attributable to shareholders was USD 3,001 million, down 14.2%, and diluted earnings per share USD 2.37.
The year to 31 December 2017, against the year before
| Year to | Dec 2016 | Dec 2017 |
|---|---|---|
| Revenue | 23,002 | 22,465 |
| Cost of sales | 4,126 | 4,318 |
| Gross profit | 18,876 | 18,147 |
| Research and development | 5,890 | 5,757 |
| Selling, general and administrative | 9,413 | 10,233 |
| Operating profit | 4,902 | 3,677 |
| Finance costs | 1,384 | 1,508 |
| Profit before tax | 3,552 | 2,227 |
| Income tax | 146 | -641 |
| Profit for the year | 3,406 | 2,868 |
| Profit attributable to shareholders | 3,499 | 3,001 |
| Filing | 20-F | 20-F |
USD million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed. A line the company does not file under the standard tag is left out rather than estimated.
USD per ordinary share, as filed.
Cash flow
| Year to | Dec 2016 | Dec 2017 |
|---|---|---|
| Cash from operations | 4,145 | 3,578 |
| Purchase of property, plant and equipment | 1,446 | 1,326 |
| Free cash flow | 2,699 | 2,252 |
| Dividends paid | 3,561 | 3,519 |
| Filing | 20-F | 20-F |
USD million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.
Balance sheet at year end
| Year to | Dec 2016 | Dec 2017 |
|---|---|---|
| Total assets | 62,526 | 63,354 |
| Equity attributable to shareholders | 14,854 | 14,960 |
| Cash and cash equivalents | 5,018 | 3,324 |
| Borrowings, as filed | n/a | 17,807 |
| Trade and other receivables | 4,573 | 5,009 |
| Inventories | 2,334 | 3,035 |
| Goodwill | 11,658 | 11,825 |
| Filing | 20-F | 20-F |
USD million, at each fiscal year end.
Ratios on the filed lines
| Year to | Dec 2016 | Dec 2017 |
|---|---|---|
| Gross margin | 82.1% | 80.8% |
| Operating margin | 21.3% | 16.4% |
| Net margin | 15.2% | 13.4% |
| Free cash flow margin | 11.7% | 10.0% |
| Return on year-end equity | 23.6% | 20.1% |
| Effective tax rate | 4.1% | -28.8% |
| Filing | 20-F | 20-F |
Arithmetic on the filed lines of the same year.
Every annual report here
- Year to 31 December 2025
- Year to 31 December 2024
- Year to 31 December 2023
- Year to 31 December 2022
- Year to 31 December 2021
- Year to 31 December 2020
- Year to 31 December 2019
- Year to 31 December 2018
- Year to 31 December 2017, this page
- Year to 31 December 2016
- Year to 31 December 2015
Source
20-F for the year to 31 December 2017, filed 3 March 2020, accession 0001104659-20-028557: the filing on EDGAR. All of AstraZeneca PLC's filings: EDGAR company page. The figures are in US dollars as filed.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.